IL124636A0 - Conditionally replicating viral vectors and their use - Google Patents
Conditionally replicating viral vectors and their useInfo
- Publication number
- IL124636A0 IL124636A0 IL12463696A IL12463696A IL124636A0 IL 124636 A0 IL124636 A0 IL 124636A0 IL 12463696 A IL12463696 A IL 12463696A IL 12463696 A IL12463696 A IL 12463696A IL 124636 A0 IL124636 A0 IL 124636A0
- Authority
- IL
- Israel
- Prior art keywords
- image
- viral
- conditionally replicating
- vector
- replicating viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56345995A | 1995-11-28 | 1995-11-28 | |
PCT/US1996/018997 WO1997020060A1 (en) | 1995-11-28 | 1996-11-27 | Conditionally replicating viral vectors and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
IL124636A0 true IL124636A0 (en) | 1998-12-06 |
Family
ID=24250568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12463696A IL124636A0 (en) | 1995-11-28 | 1996-11-27 | Conditionally replicating viral vectors and their use |
IL124636A IL124636A (en) | 1995-11-28 | 1998-05-25 | Conditionally replicating viral vectors and their use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL124636A IL124636A (en) | 1995-11-28 | 1998-05-25 | Conditionally replicating viral vectors and their use |
Country Status (19)
Country | Link |
---|---|
EP (2) | EP0871757B1 (cs) |
JP (2) | JP2000503527A (cs) |
KR (1) | KR100537458B1 (cs) |
CN (3) | CN100390291C (cs) |
AT (2) | ATE234362T1 (cs) |
AU (3) | AU1124997A (cs) |
BR (1) | BR9612574A (cs) |
CA (1) | CA2236868C (cs) |
CZ (1) | CZ294170B6 (cs) |
DE (2) | DE69626681T2 (cs) |
DK (1) | DK0871757T3 (cs) |
ES (1) | ES2188802T3 (cs) |
HK (1) | HK1060152A1 (cs) |
IL (2) | IL124636A0 (cs) |
NO (1) | NO329619B1 (cs) |
NZ (1) | NZ324157A (cs) |
PT (1) | PT871757E (cs) |
RU (1) | RU2270250C2 (cs) |
WO (1) | WO1997020060A1 (cs) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999030742A1 (en) * | 1997-12-12 | 1999-06-24 | Luigi Naldini | Therapeutic use of lentiviral vectors |
GB9803351D0 (en) * | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
AU9307501A (en) * | 2000-09-22 | 2002-04-02 | Virxsys | Improved conditionally replicating vectors, methods for their production and use |
US20030026791A1 (en) * | 2001-03-27 | 2003-02-06 | Laurent Humeau | Conditionally replicating vectors for inhibiting viral infections |
WO2009076524A2 (en) | 2007-12-11 | 2009-06-18 | The University Of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
KR102266691B1 (ko) * | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
SG10202108814VA (en) * | 2015-02-24 | 2021-09-29 | Bioatla Llc | Conditionally active biological proteins |
CN104711294A (zh) * | 2015-04-02 | 2015-06-17 | 扬州大学 | 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用 |
GB2543730A (en) * | 2015-05-26 | 2017-05-03 | Andrzejewski Slawomir | Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225337A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
IL108719A0 (en) * | 1993-02-25 | 1994-08-26 | Ortho Pharma Corp | Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them |
CA2163129A1 (en) * | 1993-05-17 | 1994-11-24 | Flossie Wong-Staal | Ribozyme gene therapy for hiv infection and aids |
NZ278432A (en) * | 1994-01-05 | 1998-06-26 | Gene Shears Pty Ltd | Oligonucleotides comprising a sequence defining a conserved catalytic region and a sequence capable of hybridizing with a predetermined target sequence in a rna virus packaging sequence |
EP0759471A4 (en) * | 1994-05-10 | 1997-10-15 | Hisamitsu Pharmaceutical Co | RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF |
TW438601B (en) * | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
-
1996
- 1996-11-27 JP JP9520658A patent/JP2000503527A/ja not_active Ceased
- 1996-11-27 CN CNB961997265A patent/CN100390291C/zh not_active Expired - Lifetime
- 1996-11-27 DE DE69626681T patent/DE69626681T2/de not_active Expired - Lifetime
- 1996-11-27 KR KR1019980704006A patent/KR100537458B1/ko not_active IP Right Cessation
- 1996-11-27 NZ NZ324157A patent/NZ324157A/xx not_active IP Right Cessation
- 1996-11-27 CN CNA2004100642461A patent/CN1651577A/zh active Pending
- 1996-11-27 CN CNA2006101018474A patent/CN1940076A/zh active Pending
- 1996-11-27 AU AU11249/97A patent/AU1124997A/en not_active Abandoned
- 1996-11-27 AT AT96942083T patent/ATE234362T1/de active
- 1996-11-27 DE DE69638120T patent/DE69638120D1/de not_active Expired - Lifetime
- 1996-11-27 EP EP96942083A patent/EP0871757B1/en not_active Expired - Lifetime
- 1996-11-27 PT PT96942083T patent/PT871757E/pt unknown
- 1996-11-27 BR BR9612574-8A patent/BR9612574A/pt not_active Application Discontinuation
- 1996-11-27 ES ES96942083T patent/ES2188802T3/es not_active Expired - Lifetime
- 1996-11-27 RU RU98112183/13A patent/RU2270250C2/ru active
- 1996-11-27 EP EP02027910A patent/EP1380650B1/en not_active Expired - Lifetime
- 1996-11-27 AT AT02027910T patent/ATE455858T1/de not_active IP Right Cessation
- 1996-11-27 CA CA2236868A patent/CA2236868C/en not_active Expired - Fee Related
- 1996-11-27 IL IL12463696A patent/IL124636A0/xx unknown
- 1996-11-27 DK DK96942083T patent/DK0871757T3/da active
- 1996-11-27 WO PCT/US1996/018997 patent/WO1997020060A1/en not_active Application Discontinuation
- 1996-11-27 CZ CZ19981624A patent/CZ294170B6/cs not_active IP Right Cessation
-
1998
- 1998-05-25 IL IL124636A patent/IL124636A/en not_active IP Right Cessation
- 1998-05-27 NO NO19982418A patent/NO329619B1/no not_active IP Right Cessation
-
2001
- 2001-01-05 AU AU10000/01A patent/AU767620B2/en not_active Ceased
-
2004
- 2004-02-20 AU AU2004200663A patent/AU2004200663B2/en not_active Ceased
- 2004-04-30 HK HK04103067.8A patent/HK1060152A1/xx not_active IP Right Cessation
-
2006
- 2006-07-28 JP JP2006206871A patent/JP4384146B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120209T1 (el) | Αλληλουχιες αδενο-εξαρτωμενου ιου (aav) οροτυπου 9, φορεις που τον περιεχουν και χρησεις αυτων | |
IL207348A0 (en) | Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them, and use thereof in the manufacture of medicinal products for producing recombinant proteins in vivo | |
RU95108217A (ru) | Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция | |
EP1312679B8 (en) | Recombinant MVA virus, and the use thereof | |
WO1996011279A3 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system | |
HUP0101432A2 (hu) | Rák kezelésére és megelőzésére alkalmas peptidek | |
DE69636032D1 (de) | Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren | |
FR2705361B1 (fr) | Vecteurs viraux et utilisation en thérapie génique. | |
CA2104396A1 (en) | Viral particles having altered host range | |
AU6117696A (en) | Nucleic acid respiratory syncytial virus vaccines | |
HUP9702377A2 (hu) | Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek | |
IL124636A0 (en) | Conditionally replicating viral vectors and their use | |
AUPN477695A0 (en) | Gene therapy | |
DK0839194T3 (da) | Varianter af P53-proteinet og terapeutiske anvendelser | |
FR2702152B1 (fr) | Virus recombinants et leur utilisation en thérapie génique. | |
AU5318496A (en) | Adenovirus vectors for gene therapy | |
FI964186A0 (fi) | Ei-liittävät gp350/220-variantit | |
WO1996040764A3 (en) | Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus | |
AU5104096A (en) | Novel recombinant dna vectors for gene therapy | |
ATE269064T1 (de) | Impfstoffe gegen den hepatitis b und c virus | |
AU5276296A (en) | Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells | |
WO2001011063A3 (de) | Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung | |
MX9709525A (es) | Vacunas de virus sincicial respiratorio de acido nucleico. |